55 results about "Tetrahydrocannabinol" patented technology

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking caffeine. Where the CBD is used in combination with caffeine, caution should be taken. For example, the dose of either the CBD and / or caffeine may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

This invention provides methods for the synthesis of cannabidiol and its analogues, as well as related compounds, formulations, and methods of use. [Solution] Methods are provided for the synthesis of oliveitol, oliveitol analogs, cannabidiol (CBD), CBD analogs, and other cannabinoids. One method uses phloroglucinol or phloroglucinol analogs as starting materials. The synthesis is stereospecific, efficient, selective, cost-effective, and THC((-)-trans-Δ 9 There is little to no possibility of generating (tetrahydro-cannabinol) or any other psychoactive by-products. Shortened synthesis is also provided, as well as new cannabinoids, pharmaceutical formulations, and methods of use.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.

There is disclosed a composition comprising delta-9-tetrahydrocannabinol, cannabidiol, cannabigerol and a terpene component.

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

The use of a small molecule compound in increasing the content of cannabidiol and tetrahydrocannabinol in cannabis. Experiments verify that a low concentration of RPS-1 can increase the content of CBD and THC in planted cannabis and, in practical production and use, reduce the production costs of CBD and THC. RPS-1 is exogenously sprayed and flexibly applied. The method does not need to change the variety and genetic background of cannabis, and can be applied to cannabis of all varieties.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. These compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as their main components, which may be isolated, purified, or extracted from cultivars and mixed together. The compositions include CBD, CBG, and THC in specific proportions, formulated for use in the treatment of PTE.

A pharmaceutically or nutraceutically acceptable formulation contains a cannabinoid which may be a full spectrum or partial spectrum cannabis extract, tetrahydrocannabinol (THC), an analog of THC, cannabidiol (CBD), an analog of CBD, ora combination thereof and at least one nootropic agent mixed in a carrier medium. A method of making the formulation mixingsaid formula and heatingthe formulation above room temperature until the mixture is homogenous. Additional supplements may be added to each formulation. The formulation may have a carrier medium suitable to be used in capsule, dissolvable tablet, vaporizer, spray, inhaler, tincture, beverage or any other suitable application.

The effect of a cationic hydrophobic polymer on improving sensitivity and selectivity toward the electrochemical detection of cannabinoid analytes, e.g. Δ9-tetrahydrocannabinol (Δ⁹-THC), has been investigated. Herein we report a rapid, inexpensive and stable method for the detection of 10 – 1000 ng / mL of cannabinoid analytes, e.g. Δ9-tetrahydrocannabinol (Δ⁹-THC), 5 in buffer solutions and in human saliva.

The present invention relates to the medical device and pharmaceutical industry, as well as related fields such as dermatology and cosmetics, since the formulation includes natural anti-inflammatory components and high viscous solvents such as polysorbate and glycerol, which work synergistically to enhance drug retention on the eye surface, minimize visual blur on instillation and reduce dosage frequency. The present invention describes a topical delivery of a cannabinoid-based ophthalmic composition that includes Tetrahydrocannabinol (THC)-based molecule isolated or associated with Cannabidiol (CBD). In another embodiment of the preferred invention, the formulation further comprises one or more synergistic agents, including but not limited to steroidal and non-steroidal anti-inflammatory and antihistamines pharmaceutical formulations.

The present invention relates to a method for preparing cannabidiol by separation and purification using high-speed countercurrent chromatography, comprising: alcohol extraction and water precipitation, adsorption with a macroporous resin, and high-speed countercurrent chromatography separation. The present invention separates and obtains high-purity cannabidiol from industrial hemp flowers or leaves, while at the same time removing the psychotoxic component tetrahydrocannabinol by combining a microporous resin chromatographic column with a high-speed countercurrent chromatograph, and optimizing process parameters, and the solvent used therein being environmentally friendly, leaving no residues, having low cost and being recyclable. Therefore, the method is suitable for industrial production.

Provided is a transdermal drug delivery system comprising tetrahydrocannabinol (THC). Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

To provide a stable, non-degradable composition comprising a pharmaceutical grade, inhalable, soluble, and highly bioavailable API.SOLUTION: A composition comprising a pharmaceutical grade cyclodextrin encapsulated active pharmaceutical ingredient (API) having a purity of 99.9% and an increased bioavailability of 200% compared to a formulation of a non-cyclodextrin encapsulated active pharmaceutical ingredient, and a pharmaceutically acceptable carrier, excipient, emulsifier, and / or binder, A water-soluble, stable, non-degradable, edible, inhalable, soluble or drinkable composition in which the active pharmaceutical ingredient is a cannabinoid and the cannabinoid is one or more of cannabidiol (CBD) or (-) - trans - δ 9-tetrahydrocannabinol (δ 9-THC).SELECTED DRAWING: None

Provided are methods of preparing cannabinol from cannabidiol and / or tetrahydrocannabinol and for preparing cannabinol acetate. The methods comprise using catalytic molecular halogen in the presence of an oxidant.

Methods of treating nonconvulsive seizures are provided. These methods include administering a THC compound, such as dronabinol or Δ9-tetrahydrocannabinol, to a patient at a therapeutically effective dose. Additional methods include combination with anti-seizure therapy as a seizure first-aid medication. Further methods provide a dose of a THC compound that minimizes or eliminates the level of adverse psychotropic effects.

Disclosed are powder compositions with a pH of at least 6 for delivery of an active agent to the nasal cavity, wherein the active agent is selected from at least one of nicotine, tetrahydrocannabinol (THC) and ethanol. The compositions comprise a filling agent of water soluble and water insoluble microcrystalline cellulose and a matrix forming agent and have a defined brightness and particle size range. Also disclosed are products including the powder compositions and support particles inducing a desired property to the product.

Compositions that include cannabinoids other than tetrahydrocannabinol (THC), such as cannabigerol (CBG) in combination with tetrahydrocannabinol (THC) or formulated to be combined with THC, and methods of preparation and use thereof are described. The compositions may be useful to reduce the risk of THC-induced anxiety and / or to produce a different intoxicating effect compared to THC alone.

The present disclosure relates to polymorphs of D9-THC-naphthoylester for the preparation of D9-Tetrahydrocannabinol in high yields and high purity, methods of preparing the D9-Tetrahydrocannabinol, and compositions comprising the D9-Tetrahydrocannabinol.

Various embodiments of a metered dose inhaler are disclosed. The inhaler includes a metering valve, a canister, and an actuator having an actuator nozzle. The canister contains a formulation having a propellant including HFA-152a, at least 1% by weight ethanol, and one or more cannabinoids, the one or more cannabinoids dissolved in the formulation to form a solution. In one or more embodiments, the cannabinoids include tetrahydrocannabinol (THC) and / or cannabidiol (CBD).

A method for irrigating a crop using a nanobubble hydrogen rich water to increase a concentration of tetrahydrocannabinol (THC) in the crop is disclosed.

A process for the synthesis of Cannabidiol of formula (1): (1) is herein disclosed. The process comprises contacting a solution [solution (S1)] of (+)-p-mentha-diene-3-ol of formula (4) (4) or an ester thereof and olivetol of formula (3): (3) with a solution [solution (S2)] of a non-supported Lewis acid in a continuous flow reactor and treatment of the resulting mixture with a basic solution. The process offers the advantage that it can be conveniently carried out on an industrial scale while avoiding the formation of abnormal CBD and THC (Δ9-tetrahydrocannabinol).

The present invention relates to compositions for use in the treatment and / or prevention of chronic musculoskeletal pain, including chronic lumbodorsal pain (CLBP), chronic non-specific lumbodorsal pain (CNSLBP), osteoarthritis and / or other chronic musculoskeletal pain affecting body parts or systems, such as joints, tendons, ligaments, bones and / or muscles, the composition comprises delta-9-tetrahydrocannabinol (THC), alpha-bisabolol, guaiacol, and beta-caryophyllene and at least one selected from the group consisting of linalool, alpha-humulene, nerolidol, caryophyllene oxide, alpha-pinene, camphene, beta-pinene, beta-myrcene, limonene, eucalyptol, ocimene, gamma-terpinene, isoterpinene, alpha-terpinene, p-cymene, and at least one selected from the group consisting of linalool, alpha-humulene, nerolidol, caryophyllene oxide, alpha-pinene, camphene, beta-pinene, beta-myrcene, limonene, eucalyptol, ocimene, gamma-terpinene and additional terpenes of isopulegol and geraniol. The invention also relates to pharmaceutical formulations comprising such compositions for use in the treatment and / or prevention of chronic musculoskeletal pain, including chronic lumbodorsal pain (CLBP), chronic non-specific lumbodorsal pain (CNSLBP), osteoarthritis and / or other chronic musculoskeletal pain affecting body parts or systems, such as joints, tendons, ligaments, bones and / or muscles. The present invention also relates to methods of treating and / or preventing chronic musculoskeletal pain, including chronic lumbodorsal pain (CLBP), chronic non-specific lumbodorsal pain (CNSLBP), osteoarthritis and / or other chronic musculoskeletal pain affecting body parts or systems, such as joints, tendons, ligaments, bones and / or muscles. The invention also relates to kits comprising such compositions.

Decarboxylated cannabis compositions and methods of making and using the same are provided. The methods produce a decarboxylated product that has more terpenes and cannabidiol preserved and less oxidation of tetrahydrocannabinol to cannabinol, compared to a decarboxylated product made by a traditional decarboxylation process.